

**Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in patients (pts) with locally advanced (LA) esophageal squamous cell carcinoma (ESCC): RATIONALE-306 subgroup analysis**

**Authors:** Eric Van Cutsem,<sup>1</sup> Jianming Xu,<sup>2</sup> Eric Raymond,<sup>3</sup> Richard Hubner,<sup>4</sup> Harry H. Yoon,<sup>5</sup> Ken Kato,<sup>6</sup> Lucjan Wyrwicz,<sup>7</sup> David Tougeron,<sup>8</sup> Sook Ryun Park,<sup>9</sup> Paula Jimenez Fonseca,<sup>10</sup> Takashi Kojima,<sup>11</sup> Ryu Ishihara,<sup>12</sup> Antonio Avallone,<sup>13</sup> Roberto Pazo-Cid,<sup>14</sup> Sheng Xu,<sup>15</sup> Sebastian Yan,<sup>16</sup> Jingwen Shi,<sup>17</sup> Xuan Kong,<sup>18</sup> Florian Lordick<sup>19</sup>

**Affiliations:** <sup>1</sup>Division of Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, Belgium; <sup>2</sup>Department of Medical Oncology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China; <sup>3</sup>Department of Medical Oncology, Paris Saint-Joseph Hospital, Paris, France; <sup>4</sup>Department of Medical Oncology, The Christie NHS Foundation Trust Manchester, and Division of Cancer Sciences, University of Manchester, Manchester, UK; <sup>5</sup>Department of Oncology, Mayo Clinic, Rochester, MN, USA; <sup>6</sup>Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan; <sup>7</sup>Department of Oncology and Radiotherapy, Maria Skłodowska-Curie National Cancer Research Institute, Warsaw, Poland; <sup>8</sup>Department of Hepato-Gastroenterology, CHU de Poitiers, Poitiers, France; <sup>9</sup>Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; <sup>10</sup>Department of Medical Oncology, Central University Hospital of Asturias, ISPA, Oviedo, Spain; <sup>11</sup>Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan; <sup>12</sup>Department of Gastroenterology, Osaka International Cancer Institute, Osaka, Japan; <sup>13</sup>Department of Medical Oncology, National Cancer Institute IRCCS-G. Pascale Foundation, Naples, Italy; <sup>14</sup>Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain; <sup>15</sup>Global Bridges at BeOne Medicines, Ltd., Shanghai, China; <sup>16</sup>Clinical Development, BeOne Medicines, Ltd., Shanghai, China; <sup>17</sup>Clinical Biomarker, BeOne Medicines, Ltd., Beijing, China; <sup>18</sup>Clinical Development, BeOne Medicines, Ltd., Shanghai, China; <sup>19</sup>Department of Medicine II (Oncology, Gastroenterology, Hepatology, Pulmonology, and Infectious Diseases), Leipzig University Medical Center and University Cancer Center Leipzig (UCCL), Leipzig, Germany.

**Character count:** 1800 (limit 1800, excluding spaces, including abstract body and disclosures)

**Background:** In RATIONALE-306 (NCT03783442), pts with metastatic/locally advanced ESCC were randomized to IV TIS 200 mg or PBO every 3 wks plus investigator-chosen CT (platinum+fluoropyrimidine/paclitaxel) until disease progression, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first. There was improvement in overall survival (OS) in the intent-to-treat (ITT) population (primary endpoint) and a subgroup of pts with PD-L1 Tumor Area Positivity (TAP) score  $\geq 10\%$  (secondary endpoint). At the 3-yr follow-up, improvement was sustained in TIS+CT (HR, 0.70; 95% CI: 0.59, 0.83) vs PBO +CT in the ITT population. We report a post hoc analysis in pts with LA ESCC.

**Methods:** Pts with LA ESCC, with non-metastatic disease and deemed unfit for surgery or definitive chemoradiation, were retrospectively selected and included in this analysis. Efficacy outcomes (OS, progression-free survival [PFS], objective response rate [ORR]) and safety were analyzed.

**Results:** At data cutoff (Aug 22, 2024), of 649 pts randomized (TIS+CT n=326; PBO+CT n=323), 88 had LA ESCC (TIS+CT n=49; PBO+CT n=39; median age 66.0 yrs; 85.2% male). At a minimum 45-month follow-up, efficacy was improved in patients with LA ESCC compared to the ITT population. The median OS for TIS+CT was 25.6 mos (95% CI: 19.4, 36.3) vs 12.3 mos (95% CI: 9.0, 21.7) for PBO+CT (HR, 0.49; 95% CI: 0.29, 0.84). Median PFS for TIS+CT was 9.7 mos (95% CI: 6.9, 19.6) compared to 6.9 mos (95% CI: 4.2, 9.7) for PBO+CT (HR, 0.56; 95% CI: 0.31, 1.01). The ORR was 61.2% (30 of 49 pts) for TIS+CT compared to 38.5% (15 of 39 pts) for PBO+CT.

Tolerability in the LA ESCC subgroup was consistent with the ITT population, with no new safety signals. Treatment-related adverse events with TIS+CT vs PBO+CT were 100.0% vs 92.3% (any grade), 59.2% vs 59.0% (grade  $\geq 3$ ), and 28.6% vs 20.5% (serious), respectively.

**Conclusion:** In this subgroup analysis of pts with LA ESCC, first-line TIS+CT showed substantial and clinically meaningful improvements in efficacy, with tolerable safety.

**Disclosure Statement:** The authors declare that there are conflicts of interest.